Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir

A once every eight-week cabotegravir (CAB) long-acting parenteral is more effective than daily oral emtricitabine and tenofovir disoproxil fumarate in preventing human immunodeficiency virus type one (HIV-1) transmission. Extending CAB dosing to a yearly injectable advances efforts for the eliminati...

Descripción completa

Detalles Bibliográficos
Autores principales: Gautam, Nagsen, McMillan, JoEllyn M., Kumar, Devendra, Bade, Aditya N., Pan, Qiaoyu, Kulkarni, Tanmay A., Li, Wenkuan, Sillman, Brady, Smith, Nathan A., Shetty, Bhagya L. Dyavar, Szlachetka, Adam, Edagwa, Benson J., Gendelman, Howard E., Alnouti, Yazen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187380/
https://www.ncbi.nlm.nih.gov/pubmed/34103484
http://dx.doi.org/10.1038/s41467-021-23668-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187380/
https://www.ncbi.nlm.nih.gov/pubmed/34103484
http://dx.doi.org/10.1038/s41467-021-23668-x

Ejemplares similares